COMMUNIQUÉS West-GlobeNewswire

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
27/03/2025
PALO ALTO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non- [...]
Ryoncil® is Now Available for Purchase in the United States
27/03/2025
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil ® (remestemcel-L) the first [...]
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
26/03/2025
Receives Court Approval for First Day Motions to Support Ongoing Business Operations SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (Nasdaq: ME), a leading human [...]
Alvotech Reports Record Results for 2024 and Provides Business Update
26/03/2025
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior year Product Revenues in 2024 reached $273 million, representing a 462% increase over prior year Adjusted EBITDA in 2024 was $108.3 [...]
Alvotech Reports Record Results for 2024 and Provides Business Update
26/03/2025
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior year Product Revenues in 2024 reached $273 million, representing a 462% increase over prior year Adjusted EBITDA in 2024 was $108.3 [...]
Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome
26/03/2025
First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26 th , at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE [...]
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
26/03/2025
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a [...]
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
26/03/2025
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for NDA Submission [...]
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
26/03/2025
Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels [...]
Tilray Successfully Prevails with Dismissal of HEXO Shareholder Lawsuit
26/03/2025
NEW YORK and LEAMINGTON, Ontario, March 26, 2025 (GLOBE NEWSWIRE) -- Tilray Brands Inc. (“ Tilray ”) (Nasdaq: TLRY; TSX: TLRY), and its subsidiary HEXO Corporation (“ HEXO ”), announced the successful dismissal of the [...]
BioCardia Reports 2024 Business Highlights and Financial Results
26/03/2025
SUNNYVALE, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Solésence Reports Record Fourth Quarter and Full-Year 2024 Financial Results
26/03/2025
Fourth quarter revenue increased 58% to a record $12.6 million Full Year 2024 revenue increased 40% to a record $52.3 million ROMEOVILLE, Ill., March 26, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (OTCQB: NANX), a leader [...]
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors
26/03/2025
WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on [...]
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
26/03/2025
Experimental treatment with CAN-2409 was associated with a median overall survival (mOS) of 24.5 months in patients with advanced NSCLC who had an inadequate response to ICI treatment, failed several chemotherapy [...]
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
26/03/2025
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e – - Both groups demonstrated [...]
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
26/03/2025
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 anticipated by year [...]
Dyadic Reports 2024 Year-End Financial Results and Business Updates
26/03/2025
Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024 Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 [...]
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
26/03/2025
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies [...]
CRISPR Therapeutics Announces Transition of Chief Operating Officer
26/03/2025
ZUG, Switzerland and BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today [...]

Pages